{"id":2082,"date":"2009-05-16T13:36:57","date_gmt":"2009-05-16T13:36:57","guid":{"rendered":"https:\/\/www.progeriaresearch.org\/?p=2082"},"modified":"2020-12-10T16:44:57","modified_gmt":"2020-12-10T21:44:57","slug":"moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins","status":"publish","type":"post","link":"https:\/\/www.progeriaresearch.org\/he\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/","title":{"rendered":"\u05de\u05ea\u05e7\u05d3\u05de\u05d9\u05dd \u05d1\u05de\u05d4\u05d9\u05e8\u05d5\u05ea \u05d4\u05d1\u05d4\u05e8\u05d4 \u05e2\u05dd \u05ea\u05d7\u05d9\u05dc\u05ea \u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d4\u05de\u05e9\u05d5\u05dc\u05e9\u05d5\u05ea \u05e9\u05dc \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4!"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2009\/05\/HayleyMichielAmber-Aug09.jpg” title_text=”HayleyMichielAmber-Aug09″ _builder_version=”4.6.5″ _module_preset=”default” hover_enabled=”0″ align=”center” sticky_enabled=”0″ custom_margin=”||-4px|||”][\/et_pb_image][et_pb_text admin_label=”caption HM” _builder_version=”4.6.5″ _module_preset=”default” text_font_size=”12px”]<\/p>\n

\u05d4\u05d9\u05d9\u05dc\u05d9 \u05de\u05d0\u05e0\u05d2\u05dc\u05d9\u05d4 \u05d5\u05de\u05d9\u05e6'\u05d9\u05d0\u05dc \u05de\u05d1\u05dc\u05d2\u05d9\u05d4 \u05db\u05d5\u05dc\u05df \u05de\u05d7\u05d9\u05d9\u05db\u05d5\u05ea \u05db\u05e9\u05d4\u05df \u05de\u05e6\u05d8\u05dc\u05de\u05d9\u05dd \u05e2\u05dd \u05d4\u05d2\u05d1\u05d9\u05e2\u05d9\u05dd \u05e9\u05dc\u05d4\u05dd \u05e2\u05dc \u05d4\u05e9\u05dc\u05de\u05ea \u05d4\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05e8\u05d0\u05e9\u05d5\u05df \u05d0\u05d9 \u05e4\u05e2\u05dd \u05d1\u05ea\u05e8\u05d5\u05e4\u05d4 \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05d1\u05d9\u05d5\u05dd \u05e9\u05d9\u05e9\u05d9, 14 \u05d1\u05d0\u05d5\u05d2\u05d5\u05e1\u05d8 2009. \u05d4\u05dd \u05d2\u05dd, \u05d9\u05d7\u05d3 \u05e2\u05dd \u05d0\u05d7\u05d5\u05ea\u05d5 \u05e9\u05dc \u05de\u05d9\u05db\u05dc \u05d0\u05de\u05d1\u05e8 (\u05de\u05d9\u05de\u05d9\u05df), \u05d4\u05e9\u05dc\u05d9\u05de\u05d5 \u05d0\u05ea \u05d4\u05d1\u05d9\u05e7\u05d5\u05e8 \u05d4\u05e8\u05d0\u05e9\u05d5\u05df \u05e9\u05dc\u05d4\u05dd \u05dc\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d4\u05de\u05e9\u05d5\u05dc\u05e9 \u05d1\u05d0\u05d5\u05ea\u05d5 \u05e9\u05d1\u05d5\u05e2.<\/em><\/strong><\/p>\n

[\/et_pb_text][et_pb_text _builder_version=”4.6.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”]<\/p>\n

\u05e7\u05e8\u05df \u05d4\u05de\u05d7\u05e7\u05e8 \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05d5\u05d1\u05d9\u05ea \u05d4\u05d7\u05d5\u05dc\u05d9\u05dd \u05dc\u05d9\u05dc\u05d3\u05d9\u05dd \u05d1\u05d1\u05d5\u05e1\u05d8\u05d5\u05df \u05e9\u05d5\u05d1 \u05e9\u05d5\u05ea\u05e4\u05d9\u05dd \u05dc\u05d1\u05d9\u05e6\u05d5\u05e2 \u05e0\u05d9\u05e1\u05d5\u05d9 \u05e7\u05dc\u05d9\u05e0\u05d9 \u05e9\u05e0\u05d9 \u05dc\u05d9\u05dc\u05d3\u05d9\u05dd \u05e2\u05dd \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4. \u05d4\u05e0\u05d9\u05e1\u05d9\u05d5\u05df \u05d4\u05de\u05e8\u05d2\u05e9 \u05d5\u05d4\u05d2\u05d3\u05d5\u05dc \u05d4\u05e8\u05d1\u05d4 \u05d9\u05d5\u05ea\u05e8 \u05db\u05d5\u05dc\u05dc 45 \u05d9\u05dc\u05d3\u05d9\u05dd \u05de-24 \u05de\u05d3\u05d9\u05e0\u05d5\u05ea, \u05d4\u05d3\u05d5\u05d1\u05e8\u05d9\u05dd 17 \u05e9\u05e4\u05d5\u05ea \u05e9\u05d5\u05e0\u05d5\u05ea!\u00a0<\/strong><\/p>\n

\u05ea\u05b7\u05e7\u05e6\u05b4\u05d9\u05e8<\/strong>: \u05d7\u05d5\u05e7\u05e8\u05d9\u05dd \u05d6\u05d9\u05d4\u05d5 \u05e9\u05ea\u05d9 \u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05e0\u05d5\u05e1\u05e4\u05d5\u05ea \u05e9\u05d1\u05e9\u05d9\u05de\u05d5\u05e9 \u05d1\u05e9\u05d9\u05dc\u05d5\u05d1 \u05e2\u05dd \u05ea\u05e8\u05d5\u05e4\u05ea \u05d4-FTI \u05d4\u05e0\u05d5\u05db\u05d7\u05d9\u05ea \u05d4\u05e0\u05d1\u05d3\u05e7\u05ea, \u05e2\u05e9\u05d5\u05d9\u05d5\u05ea \u05dc\u05e1\u05e4\u05e7 \u05d8\u05d9\u05e4\u05d5\u05dc \u05d9\u05e2\u05d9\u05dc \u05d0\u05e4\u05d9\u05dc\u05d5 \u05d9\u05d5\u05ea\u05e8 \u05dc\u05d9\u05dc\u05d3\u05d9\u05dd \u05e2\u05dd \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05de\u05d0\u05e9\u05e8 \u05ea\u05e8\u05d5\u05e4\u05d5\u05ea FTI \u05d1\u05dc\u05d1\u05d3.<\/p>\n

\u05d1\u05e1\u05d9\u05e1 \u05de\u05d3\u05e2\u05d9 \u05dc\u05d8\u05d9\u05e4\u05d5\u05dc<\/strong><\/div>\n
\u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05e0\u05d2\u05e8\u05de\u05ea \u05de\u05d7\u05dc\u05d1\u05d5\u05df \u05dc\u05d0 \u05ea\u05e7\u05d9\u05df \u05d1\u05e9\u05dd \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05df. \u05e6\u05d5\u05d5\u05ea \u05d4\u05de\u05d7\u05e7\u05e8 \u05e9\u05dc \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05d1\u05d1\u05d9\u05ea \u05d4\u05d7\u05d5\u05dc\u05d9\u05dd \u05dc\u05d9\u05dc\u05d3\u05d9\u05dd \u05d1\u05d1\u05d5\u05e1\u05d8\u05d5\u05df \u05d9\u05d5\u05e1\u05d9\u05e3 \u05e9\u05ea\u05d9 \u05ea\u05e8\u05d5\u05e4\u05d5\u05ea, \u05d4\u05e0\u05e7\u05e8\u05d0\u05d5\u05ea \u05e4\u05e8\u05d1\u05e1\u05d8\u05d8\u05d9\u05df \u05d5\u05d6\u05d5\u05dc\u05d3\u05e8\u05d5\u05e0\u05d0\u05d8, \u05dc\u05d8\u05d9\u05e4\u05d5\u05dc \u05d4\u05e0\u05d5\u05db\u05d7\u05d9 \u05d1-FTI.<\/div>\n
\u00a0<\/div>\n
\u05d0\u05b4\u05e1\u05d8\u05e8\u05b8\u05d8\u05b6\u05d2\u05b4\u05d9\u05b8\u05d4:<\/em><\/strong> \u05db\u05dc \u05e9\u05dc\u05d5\u05e9 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d9\u05ea\u05de\u05e7\u05d3\u05d5 \u05d1\u05e0\u05e7\u05d5\u05d3\u05d5\u05ea \u05e9\u05d5\u05e0\u05d5\u05ea \u05dc\u05d0\u05d5\u05e8\u05da \u05d4\u05de\u05e1\u05dc\u05d5\u05dc \u05d4\u05de\u05d5\u05d1\u05d9\u05dc \u05dc\u05d9\u05d9\u05e6\u05d5\u05e8 \u05d4\u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05df \u05d4\u05d2\u05d5\u05e8\u05dd \u05dc\u05de\u05d7\u05dc\u05d4. \u05d1\u05de\u05d7\u05e7\u05e8\u05d9 \u05de\u05e2\u05d1\u05d3\u05d4 \u05de\u05e8\u05d2\u05e9\u05d9\u05dd \u05e9\u05d4\u05d5\u05e6\u05d2\u05d5 \u05e2\u05dc \u05d9\u05d3\u05d9 \u05d3"\u05e8 \u05e7\u05e8\u05dc\u05d5\u05e1 \u05dc\u05d5\u05e4\u05d6-\u05d0\u05d5\u05d8\u05d9\u05df \u05de\u05e1\u05e4\u05e8\u05d3 \u05d1\u05e1\u05d3\u05e0\u05d4 \u05d4\u05de\u05d3\u05e2\u05d9\u05ea \u05e9\u05dc \u05e7\u05e8\u05df \u05d4\u05de\u05d7\u05e7\u05e8 \u05e9\u05dc \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05d1-2007, \u05e9\u05ea\u05d9 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d4\u05d7\u05d3\u05e9\u05d5\u05ea \u05e9\u05d9\u05e4\u05e8\u05d5 \u05d0\u05ea \u05d4\u05de\u05d7\u05dc\u05d4 \u05d1\u05ea\u05d0\u05d9 \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05d5\u05d4\u05d0\u05e8\u05d9\u05db\u05d5 \u05d0\u05ea \u05ea\u05d5\u05d7\u05dc\u05ea \u05d4\u05d7\u05d9\u05d9\u05dd \u05d1\u05d3\u05d2\u05de\u05d9 \u05e2\u05db\u05d1\u05e8\u05d9\u05dd \u05e9\u05dc \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4.<\/div>\n
\u00a0<\/strong><\/div>\n
\u05d9\u05b7\u05e2\u05b7\u05d3:<\/em><\/strong> \u05d0\u05dd \u05e9\u05dc\u05d5\u05e9 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d4\u05e0\u05d9\u05ea\u05e0\u05d5\u05ea \u05d1\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d6\u05d4 \u05d9\u05db\u05d5\u05dc\u05d5\u05ea \u05dc\u05d7\u05e1\u05d5\u05dd \u05d1\u05d9\u05e2\u05d9\u05dc\u05d5\u05ea \u05d0\u05ea \u05d4\u05d4\u05ea\u05e7\u05e9\u05e8\u05d5\u05ea \u05e9\u05dc \u05e7\u05d1\u05d5\u05e6\u05ea \u05e4\u05e8\u05e0\u05e1\u05d9\u05dc \u05d6\u05d5, \u05d0\u05d6\u05d9 \u05d4\u05e4\u05e8\u05d5\u05d2'\u05e8\u05d9\u05df \u05e2\u05e9\u05d5\u05d9 \u05dc\u05d4\u05d9\u05d5\u05ea "\u05de\u05e9\u05d5\u05ea\u05e7" \u05d5\u05d4\u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05e2\u05e9\u05d5\u05d9\u05d4 \u05dc\u05d4\u05e9\u05ea\u05e4\u05e8. \u05d0\u05e0\u05d5 \u05de\u05e7\u05d5\u05d5\u05d9\u05dd \u05e9\u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d9\u05e2\u05d1\u05d3\u05d5 \u05db\u05e9\u05d5\u05ea\u05e4\u05d5\u05ea, \u05db\u05d3\u05d9 \u05dc\u05d4\u05e9\u05dc\u05d9\u05dd \u05d6\u05d5 \u05d0\u05ea \u05d6\u05d5 \u05db\u05da \u05e9\u05d7\u05dc\u05d1\u05d5\u05df \u05d4\u05e4\u05e8\u05d5\u05d2'\u05e8\u05d9\u05df \u05d9\u05d5\u05e9\u05e4\u05e2 \u05d9\u05d5\u05ea\u05e8 \u05de\u05e9\u05d9\u05dc\u05d5\u05d1 \u05e9\u05dc\u05d5\u05e9 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05de\u05d0\u05e9\u05e8 \u05e9\u05d9\u05de\u05d5\u05e9 \u05d1\u05db\u05dc \u05ea\u05e8\u05d5\u05e4\u05d4 \u05d0\u05d7\u05ea \u05d1\u05dc\u05d1\u05d3.<\/div>\n
\u00a0<\/div>\n
\u05de\u05d9 \u05e0\u05e8\u05e9\u05dd \u05dc\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05e1\u05de\u05d9\u05dd \u05d4\u05de\u05e9\u05d5\u05dc\u05e9?<\/strong><\/div>\n
\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05d4\u05d9\u05ea\u05db\u05e0\u05d5\u05ea:<\/strong>\u00a0\u05d4\u05e6\u05d5\u05d5\u05ea \u05db\u05d1\u05e8 \u05e2\u05e8\u05da \u05de\u05d9\u05e0\u05d9 \u05e0\u05d9\u05e1\u05d5\u05d9 \u05dc-5 \u05d9\u05dc\u05d3\u05d9\u05dd \u05e2\u05dd \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4. \u05e0\u05d9\u05e1\u05d5\u05d9 "\u05d4\u05d9\u05ea\u05db\u05e0\u05d5\u05ea" \u05d4\u05e7\u05e6\u05e8, \u05d7\u05d5\u05d3\u05e9 \u05d0\u05d7\u05d3, \u05e9\u05d0\u05dc \u05d4\u05d0\u05dd \u05e9\u05d9\u05dc\u05d5\u05d1 \u05e9\u05dc\u05d5\u05e9 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05e0\u05e1\u05d1\u05dc \u05d4\u05d9\u05d8\u05d1, \u05dc\u05e4\u05e0\u05d9 \u05ea\u05d7\u05d9\u05dc\u05ea \u05e0\u05d9\u05e1\u05d5\u05d9 \u05d1\u05d9\u05e0\u05dc\u05d0\u05d5\u05de\u05d9 \u05d2\u05d3\u05d5\u05dc \u05d9\u05d5\u05ea\u05e8. \u05ea\u05d5\u05e4\u05e2\u05d5\u05ea \u05d4\u05dc\u05d5\u05d5\u05d0\u05d9 \u05d4\u05d9\u05d5 \u05de\u05e7\u05d5\u05d1\u05dc\u05d5\u05ea, \u05d5\u05d4\u05e6\u05d5\u05d5\u05ea \u05e2\u05d1\u05e8 \u05dc\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05d9\u05e2\u05d9\u05dc\u05d5\u05ea \u05d4\u05d2\u05d3\u05d5\u05dc \u05d9\u05d5\u05ea\u05e8.<\/div>\n
\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05d9\u05e2\u05d9\u05dc\u05d5\u05ea:<\/strong> \u05d1\u05d9\u05e0\u05d5\u05d0\u05e8 2010, \u05e7\u05e8\u05df \u05d4\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05de\u05e9\u05d5\u05dc\u05e9\u05ea \u05e0\u05e8\u05e9\u05de\u05d4 \u05d1\u05de\u05dc\u05d5\u05d0\u05d4 \u05e2\u05dd 45 \u05d9\u05dc\u05d3\u05d9\u05dd. \u05d6\u05d4 \u05db\u05d5\u05dc\u05dc \u05d9\u05dc\u05d3\u05d9\u05dd \u05d4\u05de\u05e9\u05ea\u05ea\u05e4\u05d9\u05dd \u05d1\u05e0\u05d9\u05e1\u05d5\u05d9 FTI \u05d1\u05dc\u05d1\u05d3, \u05d4-5 \u05d1\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05d4\u05d9\u05ea\u05db\u05e0\u05d5\u05ea, \u05d5\u05d9\u05dc\u05d3\u05d9\u05dd \u05d0\u05d7\u05e8\u05d9\u05dd \u05e9\u05d4\u05d9\u05d5 \u05e6\u05e2\u05d9\u05e8\u05d9\u05dd \u05de\u05db\u05d3\u05d9 \u05dc\u05d4\u05e9\u05ea\u05ea\u05e3 \u05d1\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05e8\u05d0\u05e9\u05d5\u05df \u05d0\u05d5 \u05d9\u05dc\u05d3\u05d9\u05dd \u05e9\u05d2\u05d9\u05dc\u05d9\u05e0\u05d5 \u05d1\u05de\u05d4\u05dc\u05da \u05d4\u05e9\u05e0\u05ea\u05d9\u05d9\u05dd \u05d4\u05d0\u05d7\u05e8\u05d5\u05e0\u05d5\u05ea. \u05dc\u05d9\u05dc\u05d3\u05d9\u05dd \u05e9\u05e0\u05e8\u05e9\u05de\u05d5 \u05dc\u05e0\u05d9\u05e1\u05d5\u05d9 FTI \u05d1\u05dc\u05d1\u05d3 \u05d4\u05d9\u05d9\u05ea\u05d4 \u05d4\u05d6\u05d3\u05de\u05e0\u05d5\u05ea \u05dc\u05d4\u05d9\u05e8\u05e9\u05dd \u05dc\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05de\u05e9\u05d5\u05dc\u05e9 \u05db\u05e9\u05d4\u05d2\u05d9\u05e2\u05d5 \u05dc\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05e8\u05d0\u05e9\u05d5\u05df \u05d4\u05d6\u05d4. \u05d6\u05d4 \u05d0\u05d9\u05e4\u05e9\u05e8 \u05dc\u05d9\u05dc\u05d3\u05d9\u05dd \u05dc\u05d4\u05de\u05e9\u05d9\u05da \u05dc\u05e7\u05d7\u05ea FTI \u05dc\u05dc\u05d0 \u05de\u05e0\u05d5\u05ea \u05e9\u05d4\u05d5\u05d7\u05de\u05e6\u05d5.<\/div>\n
\u00a0<\/strong><\/div>\n
\u05de\u05e2\u05e8\u05db\u05ea \u05d4\u05d9\u05d7\u05e1\u05d9\u05dd \u05d4\u05d8\u05d9\u05e4\u05d5\u05dc\/\u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4<\/strong><\/div>\n
\u05d0\u05d9\u05da \u05d4\u05d2\u05e2\u05e0\u05d5 \u05de\u05d2\u05d9\u05dc\u05d5\u05d9 \u05d2\u05e0\u05d9\u05dd \u05dc\u05d8\u05d9\u05e4\u05d5\u05dc \u05ea\u05e8\u05d5\u05e4\u05ea\u05d9 \u05dc\u05d9\u05dc\u05d3\u05d9\u05dd \u05e2\u05dd \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4? \u05de\u05e6\u05d9\u05d0\u05ea \u05d4\u05d2\u05df \u05dc\u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05d4\u05d9\u05d4 \u05d4\u05de\u05e4\u05ea\u05d7. \u05d4\u05d2\u05df \u05d4\u05d6\u05d4 \u05e0\u05e7\u05e8\u05d0 LMNA<\/em>, \u05d5\u05d1\u05d3\u05e8\u05da \u05db\u05dc\u05dc \u05d4\u05d5\u05d0 \u05de\u05e7\u05d5\u05d3\u05d3 \u05dc\u05d7\u05dc\u05d1\u05d5\u05df \u05d4\u05e0\u05e7\u05e8\u05d0 \u05e4\u05e8\u05dc\u05de\u05d9\u05df A (\u05d7\u05dc\u05d1\u05d5\u05df \u05d6\u05d4 \u05de\u05e2\u05d5\u05d1\u05d3 \u05d1\u05d4\u05de\u05e9\u05da \u05d5\u05d4\u05d5\u05e4\u05da \u05dc\u05dc\u05de\u05d9\u05df A). \u05dc\u05d9\u05dc\u05d3\u05d9\u05dd \u05e2\u05dd \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05d9\u05e9 \u05de\u05d5\u05d8\u05e6\u05d9\u05d4 LMNA<\/em> \u05de\u05d4 \u05e9\u05de\u05d5\u05d1\u05d9\u05dc \u05dc\u05d9\u05d9\u05e6\u05d5\u05e8 \u05e9\u05dc \u05e6\u05d5\u05e8\u05d4 \u05d7\u05e8\u05d9\u05d2\u05d4 \u05e9\u05dc \u05e4\u05e8\u05dc\u05de\u05d9\u05df A \u05d4\u05e0\u05e7\u05e8\u05d0\u05ea "\u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05df". \u05de\u05d7\u05e7\u05e8 \u05d1\u05e1\u05d9\u05e1\u05d9 \u05e9\u05dc \u05e9\u05e0\u05d9\u05dd \u05e8\u05d1\u05d5\u05ea \u05e2\u05dc \u05e4\u05e8\u05dc\u05de\u05d9\u05df A \u05d5\u05dc\u05de\u05d9\u05df A \u05e0\u05ea\u05df \u05dc\u05e0\u05d5 \u05d0\u05ea \u05d4\u05d9\u05db\u05d5\u05dc\u05ea \u05dc\u05d4\u05d1\u05d9\u05df \u05e9\u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d4\u05e0\u05d9\u05ea\u05e0\u05d5\u05ea \u05d1\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d6\u05d4 \u05e2\u05e9\u05d5\u05d9\u05d5\u05ea \u05dc\u05d4\u05e9\u05e4\u05d9\u05e2 \u05e2\u05dc \u05d4\u05de\u05d7\u05dc\u05d4 \u05d1\u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4. \u05d1\u05de\u05d4\u05dc\u05da \u05e9\u05e9 \u05d4\u05e9\u05e0\u05d9\u05dd \u05d4\u05d0\u05d7\u05e8\u05d5\u05e0\u05d5\u05ea, \u05d4\u05de\u05d7\u05e7\u05e8 \u05d4\u05ea\u05de\u05e7\u05d3 \u05d1\u05d1\u05d3\u05d9\u05e7\u05d4 \u05e9\u05d9\u05d8\u05ea\u05d9\u05ea \u05e9\u05dc \u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d0\u05dc\u05d5 \u05e2\u05dc \u05ea\u05d0\u05d9 \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05d5\u05e2\u05db\u05d1\u05e8\u05d9 \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4.<\/div>\n
\u00a0<\/div>\n
\u05e6\u05d5\u05d5\u05ea \u05d4\u05e0\u05d9\u05e1\u05d5\u05d9\u05d9\u05dd \u05d4\u05e7\u05dc\u05d9\u05e0\u05d9\u05d9\u05dd<\/strong><\/div>\n
\u05de\u05d0\u05d6 \u05de\u05d0\u05d9 2007, \u05e6\u05d5\u05d5\u05ea \u05e9\u05dc 28 \u05d7\u05d1\u05e8\u05d9\u05dd \u05d8\u05d9\u05e4\u05dc \u05d1\u05d9\u05dc\u05d3\u05d9\u05dd \u05e2\u05dd \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05de\u05e8\u05d7\u05d1\u05d9 \u05d4\u05e2\u05d5\u05dc\u05dd. \u05dc\u05d7\u05d1\u05e8\u05d9 \u05d4\u05e6\u05d5\u05d5\u05ea \u05d9\u05e9 \u05de\u05d5\u05de\u05d7\u05d9\u05d5\u05ea \u05dc\u05d0 \u05e8\u05e7 \u05d1\u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4, \u05d0\u05dc\u05d0 \u05d2\u05dd \u05d1\u05e9\u05dc\u05d5\u05e9 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d4\u05e0\u05d9\u05ea\u05e0\u05d5\u05ea \u05d1\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d6\u05d4.<\/div>\n
\u00a0<\/strong><\/div>\n
\u05e0\u05d9\u05e1\u05d5\u05d9 \u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d1\u05de\u05d1\u05d8 \u05d7\u05d8\u05d5\u05e3<\/strong><\/div>\n
\u05e4\u05e8\u05d0\u05d1\u05e1\u05d8\u05d8\u05d9\u05df<\/strong> (\u05de\u05e9\u05d5\u05d5\u05e7 \u05d1\u05e9\u05dd Pravachol \u05d0\u05d5 Selektine) \u05d4\u05d5\u05d0 \u05d7\u05d1\u05e8 \u05d1\u05e7\u05d1\u05d5\u05e6\u05ea \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05e9\u05dc \u05e1\u05d8\u05d8\u05d9\u05e0\u05d9\u05dd. \u05d4\u05d5\u05d0 \u05de\u05e9\u05de\u05e9 \u05d1\u05d3\u05e8\u05da \u05db\u05dc\u05dc \u05dc\u05d4\u05d5\u05e8\u05d3\u05ea \u05db\u05d5\u05dc\u05e1\u05d8\u05e8\u05d5\u05dc \u05d5\u05de\u05e0\u05d9\u05e2\u05ea \u05de\u05d7\u05dc\u05d5\u05ea \u05dc\u05d1 \u05d5\u05db\u05dc\u05d9 \u05d3\u05dd.<\/div>\n
\u05d7\u05d5\u05de\u05e6\u05d4 \u05d6\u05d5\u05dc\u05d3\u05e8\u05d5\u05e0\u05d9\u05ea <\/strong>\u05d4\u05d5\u05d0 \u05d0 \u05d1\u05d9\u05e1\u05e4\u05d5\u05e1\u05e4\u05d5\u05e0\u05d8, <\/strong>\u05de\u05e9\u05de\u05e9 \u05d1\u05d3\u05e8\u05da \u05db\u05dc\u05dc \u05db\u05ea\u05e8\u05d5\u05e4\u05d4 \u05dc\u05e2\u05e6\u05de\u05d5\u05ea \u05dc\u05e9\u05d9\u05e4\u05d5\u05e8 \u05d0\u05d5\u05e1\u05d8\u05d0\u05d5\u05e4\u05d5\u05e8\u05d5\u05d6\u05d9\u05e1, \u05d5\u05dc\u05de\u05e0\u05d9\u05e2\u05ea \u05e9\u05d1\u05e8\u05d9\u05dd \u05d1\u05e9\u05dc\u05d3 \u05d1\u05d0\u05e0\u05e9\u05d9\u05dd \u05d4\u05e1\u05d5\u05d1\u05dc\u05d9\u05dd \u05de\u05e6\u05d5\u05e8\u05d5\u05ea \u05de\u05e1\u05d5\u05d9\u05de\u05d5\u05ea \u05e9\u05dc \u05e1\u05e8\u05d8\u05df.<\/div>\n
\u05dc\u05d5\u05e0\u05e4\u05e8\u05e0\u05d9\u05d1<\/strong> \u05d4\u05d5\u05d0 FTI<\/strong> (\u05de\u05e2\u05db\u05d1 Farnesyltransferase), \u05ea\u05e8\u05d5\u05e4\u05d4 \u05e9\u05d9\u05db\u05d5\u05dc\u05d4 \u05dc\u05d4\u05e4\u05d5\u05da \u05d7\u05e8\u05d9\u05d2\u05d4 \u05d1\u05ea\u05d0\u05d9 \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4 \u05d1\u05de\u05e2\u05d1\u05d3\u05d4, \u05d5\u05e9\u05d9\u05e4\u05e8\u05d4 \u05de\u05d7\u05dc\u05d4 \u05d1\u05e2\u05db\u05d1\u05e8\u05d9 \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4.<\/div>\n
\u05db\u05dc 3 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d7\u05d5\u05e1\u05de\u05d5\u05ea \u05d0\u05ea \u05d9\u05d9\u05e6\u05d5\u05e8 \u05de\u05d5\u05dc\u05e7\u05d5\u05dc\u05ea \u05d4\u05e4\u05e8\u05e0\u05e1\u05d9\u05dc \u05d4\u05d3\u05e8\u05d5\u05e9\u05d4 \u05dc\u05e4\u05e8\u05d5\u05d2'\u05e8\u05d9\u05df \u05dc\u05d9\u05e6\u05d9\u05e8\u05ea \u05de\u05d7\u05dc\u05d4 \u05d1\u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4.<\/em><\/div>\n
\u00a0<\/strong><\/div>\n
\u05ea\u05b4\u05d6\u05de\u05d5\u05bc\u05df<\/strong><\/div>\n
\u05de\u05d8\u05d5\u05e4\u05dc\u05d9\u05dd \u05e0\u05d5\u05e1\u05e2\u05d9\u05dd \u05dc\u05d1\u05d5\u05e1\u05d8\u05d5\u05df \u05dc\u05d1\u05d3\u05d9\u05e7\u05d5\u05ea \u05d5\u05d1\u05d3\u05d9\u05e7\u05d5\u05ea \u05d4\u05e0\u05de\u05e9\u05db\u05d5\u05ea 4-7 \u05d9\u05de\u05d9\u05dd, \u05db\u05dc 6 \u05d7\u05d5\u05d3\u05e9\u05d9\u05dd \u05dc\u05ea\u05e7\u05d5\u05e4\u05d4 \u05e9\u05dc \u05e9\u05e0\u05ea\u05d9\u05d9\u05dd. \u05e2\u05d1\u05d5\u05e8 \u05e0\u05d9\u05e1\u05d5\u05d9 FTI \u05d1\u05dc\u05d1\u05d3, \u05d1\u05d9\u05e7\u05d5\u05e8\u05d9\u05dd \u05d1\u05d1\u05d5\u05e1\u05d8\u05d5\u05df \u05d4\u05ea\u05e8\u05d7\u05e9\u05d5 \u05db\u05dc \u05d0\u05e8\u05d1\u05e2\u05d4 \u05d7\u05d5\u05d3\u05e9\u05d9\u05dd.<\/div>\n
\u00a0<\/strong><\/div>\n
\u05e2\u05b2\u05dc\u05d5\u05bc\u05ea<\/strong>
\u05db\u05de\u05d5\u05d1\u05df, \u05e0\u05d9\u05e1\u05d5\u05d9 \u05e7\u05dc\u05d9\u05e0\u05d9 \u05d1\u05e1\u05d3\u05e8 \u05d2\u05d5\u05d3\u05dc \u05db\u05d6\u05d4 \u05d4\u05d5\u05d0 \u05d9\u05e7\u05e8 \u05dc\u05e0\u05d9\u05d4\u05d5\u05dc, \u05d5\u05d9\u05e9 \u05de\u05e2\u05d8 \u05de\u05d0\u05d5\u05d3 \u05de\u05e7\u05d5\u05e8\u05d5\u05ea \u05ea\u05de\u05d9\u05db\u05d4 \u05dc\u05de\u05d7\u05e7\u05e8 \u05de\u05d7\u05dc\u05d5\u05ea \u05e0\u05d3\u05d9\u05e8\u05d5\u05ea. \u05d0\u05d1\u05dc \u05d1\u05d0\u05d5\u05e7\u05d8\u05d5\u05d1\u05e8 2009, \u05de\u05db\u05d5\u05df \u05d4\u05dc\u05d1, \u05d4\u05e8\u05d9\u05d0\u05d5\u05ea \u05d5\u05d4\u05d3\u05dd \u05d4\u05dc\u05d0\u05d5\u05de\u05d9 \u05e9\u05dc \u05d4-NIH \u05d4\u05e2\u05e0\u05d9\u05e7 \u05dc\u05e6\u05d5\u05d5\u05ea \u05d4\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05de\u05e9\u05d5\u05dc\u05e9 \u05de\u05e2\u05e0\u05e7 \u05d9\u05d5\u05e7\u05e8\u05ea\u05d9 "\u05d4\u05d6\u05d3\u05de\u05e0\u05d5\u05d9\u05d5\u05ea \u05d2\u05d3\u05d5\u05dc\u05d5\u05ea" \u05e9\u05d9\u05db\u05e1\u05d4 \u05e8\u05d1\u05d5\u05ea \u05de\u05d4\u05e2\u05dc\u05d5\u05d9\u05d5\u05ea. \u05d0\u05e0\u05d5 \u05e0\u05e8\u05d2\u05e9\u05d9\u05dd \u05e9\u05d6\u05db\u05d9\u05e0\u05d5 \u05dc\u05ea\u05de\u05d9\u05db\u05d4 \u05d9\u05d5\u05e6\u05d0\u05ea \u05d3\u05d5\u05e4\u05df \u05d6\u05d5 \u05de-NIH.<\/div>\n
\n

\u05e2\u05dd \u05d6\u05d0\u05ea, \u05d4\u05de\u05e2\u05e0\u05e7 \u05d0\u05d9\u05e0\u05d5 \u05de\u05db\u05e1\u05d4 \u05d0\u05ea \u05db\u05dc \u05d4\u05d5\u05e6\u05d0\u05d5\u05ea \u05d4\u05e0\u05d9\u05e1\u05d9\u05d5\u05df. PRF \u05e2\u05d3\u05d9\u05d9\u05df \u05e6\u05e8\u05d9\u05da \u05dc\u05d2\u05d9\u05d9\u05e1 \u05db-$150,000 \u05e2\u05d1\u05d5\u05e8 \u05d7\u05dc\u05e7 \u05de\u05d4\u05e2\u05dc\u05d5\u05d9\u05d5\u05ea \u05e9\u05d0\u05d9\u05e0\u05df \u05de\u05db\u05d5\u05e1\u05d5\u05ea \u05e2\u05dc \u05d9\u05d3\u05d9 \u05d4\u05de\u05e2\u05e0\u05e7.<\/p>\n

\u05dc\u05d7\u05e5 \u05db\u05d0\u05df<\/a> \u05dc\u05ea\u05e8\u05d5\u05dd \u05dc\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d4\u05de\u05e9\u05d5\u05dc\u05e9 \u05d5\u05dc\u05e2\u05d6\u05d5\u05e8 \u05dc\u05d4\u05e4\u05d5\u05da \u05d0\u05ea \u05de\u05d8\u05e8\u05ea \u05d4\u05d8\u05d9\u05e4\u05d5\u05dc \u05d5\u05d4\u05e8\u05d9\u05e4\u05d5\u05d9 \u05dc\u05de\u05e6\u05d9\u05d0\u05d5\u05ea!
<\/strong><\/p>\n<\/div>\n

* <\/em>"\u05d8\u05d9\u05e4\u05d5\u05dc \u05de\u05e9\u05d5\u05dc\u05d1 \u05e2\u05dd \u05e1\u05d8\u05d8\u05d9\u05e0\u05d9\u05dd \u05d5\u05d0\u05de\u05d9\u05e0\u05d5\u05d1\u05d9\u05e4\u05d5\u05e1\u05e4\u05d5\u05e0\u05d8\u05d9\u05dd \u05de\u05d0\u05e8\u05d9\u05da \u05d0\u05e8\u05d9\u05db\u05d5\u05ea \u05d9\u05de\u05d9\u05dd \u05d1\u05de\u05d5\u05d3\u05dc \u05e2\u05db\u05d1\u05e8 \u05e9\u05dc \u05d4\u05d6\u05d3\u05e7\u05e0\u05d5\u05ea \u05de\u05d5\u05e7\u05d3\u05de\u05ea \u05e9\u05dc \u05d4\u05d0\u05d3\u05dd",<\/strong> \u05de\u05d0\u05ea Ignacio Varela, Sandrine Pereira, Alejandro P. Ugalde, Claire L. Navarro, Mar\u00c4\u00b1a F. Suarez, Pierre Cau, Juan Cadinanos, Fernando G. Osorio, Nicolas Foray, Juan Cobo, Felix de Carlos, Nicolas Levy, Jose MP \u05e4\u05e8\u05d9\u05d9\u05d4 \u05d5\u05e7\u05e8\u05dc\u05d5\u05e1 \u05dc\u05d5\u05e4\u05d6-\u05d0\u05d5\u05d8\u05e0. \u05e8\u05e4\u05d5\u05d0\u05ea \u05d8\u05d1\u05e2, <\/em>2008. 14(7): \u05e2\u05de'. 767-72.<\/em><\/div>\n
\u00a0<\/em>
<\/em>\u05d8<\/strong>\u05d4\u05d3\u05d5\u05e8 \u05d4\u05d7\u05d3\u05e9 \u05e9\u05dc \u05d9\u05dc\u05d3\u05d9\u05dd PRF \u05e2\u05d5\u05d6\u05e8...<\/strong><\/div>\n
\u05d1\u05de\u05e8\u05e5 2009, \u05d7\u05de\u05d9\u05e9\u05d4 \u05d9\u05dc\u05d3\u05d9\u05dd, \u05d1\u05d2\u05d9\u05dc\u05d0\u05d9 2-3, \u05d4\u05e9\u05ea\u05ea\u05e4\u05d5 \u05d1\u05de\u05d7\u05e7\u05e8 \u05d4\u05d9\u05ea\u05db\u05e0\u05d5\u05ea \u05d1\u05df \u05d7\u05d5\u05d3\u05e9 \u05db\u05d3\u05d9 \u05dc\u05e7\u05d1\u05d5\u05e2 \u05d0\u05dd \u05ea\u05d5\u05e4\u05e2\u05d5\u05ea \u05d4\u05dc\u05d5\u05d5\u05d0\u05d9 \u05e9\u05dc \u05e9\u05dc\u05d5\u05e9 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05e9\u05e0\u05dc\u05e7\u05d7\u05d5 \u05d9\u05d7\u05d3 \u05d4\u05d9\u05d5 \u05e0\u05e1\u05d1\u05dc\u05d5\u05ea. \u05d4\u05ea\u05d5\u05e6\u05d0\u05d5\u05ea \u05d4\u05d9\u05d5 \u05d7\u05d9\u05d5\u05d1\u05d9\u05d5\u05ea, \u05d5\u05e1\u05dc\u05dc\u05d5 \u05d0\u05ea \u05d4\u05d3\u05e8\u05da \u05dc\u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d4\u05de\u05e9\u05d5\u05dc\u05e9 \u05d4\u05de\u05dc\u05d0, \u05d1\u05df \u05e9\u05e0\u05ea\u05d9\u05d9\u05dd, \u05dc\u05e8\u05e9\u05d5\u05dd \u05e2\u05d3 45 \u05d9\u05dc\u05d3\u05d9\u05dd \u05e2\u05dd \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4.\u00a0\u05de\u05d5\u05e8\u05d9\u05d3 \u05d0\u05ea \u05d4\u05db\u05d5\u05d1\u05e2 \u05d1\u05e4\u05e0\u05d9 \u05d4\u05de\u05e9\u05e4\u05d7\u05d5\u05ea \u05d4\u05de\u05d3\u05d4\u05d9\u05de\u05d5\u05ea \u05d4\u05d0\u05dc\u05d4!<\/strong><\/div>\n
\u00a0<\/strong><\/div>\n
\u05d4\u05e0\u05d4 \u05de\u05d4 \u05e9\u05d4\u05d9\u05d4 \u05dc\u05d7\u05dc\u05e7 \u05de\u05d4\u05dd \u05dc\u05d5\u05de\u05e8:<\/strong><\/div>\n

\"\""<\/em>\u05db\u05d5\u05dc\u05dd \u05d4\u05d9\u05d5 \u05db\u05dc \u05db\u05da \u05e0\u05e4\u05dc\u05d0\u05d9\u05dd. \u05e2\u05d1\u05d5\u05e8\u05e0\u05d5 \u05db\u05d5\u05dc\u05db\u05dd \u05d0\u05dc\u05d5\u05d4\u05d9\u05dd \u05e9\u05e0\u05e9\u05dc\u05d7\u05d5 \u05d5\u05d0\u05e0\u05d7\u05e0\u05d5 \u05de\u05e2\u05e8\u05d9\u05db\u05d9\u05dd \u05d0\u05ea \u05db\u05dc \u05de\u05d4 \u05e9\u05d0\u05ea\u05dd \u05e2\u05d5\u05e9\u05d9\u05dd \u05dc\u05de\u05e2\u05df \u05d4\u05de\u05dc\u05d0\u05db\u05d9\u05dd \u05d4\u05e7\u05d8\u05e0\u05d9\u05dd \u05d4\u05d0\u05dc\u05d4. \u05d4\u05de\u05e9\u05e4\u05d7\u05d4 \u05e9\u05dc\u05e0\u05d5 \u05db\u05dc \u05db\u05da \u05d4\u05de\u05d5\u05de\u05d4 \u05de\u05d4\u05ea\u05e8\u05d2\u05e9\u05d5\u05ea \u05d5\u05de\u05db\u05dc \u05de\u05d9\u05e0\u05d9 \u05e8\u05d2\u05e9\u05d5\u05ea \u05e2\u05dd \u05d4\u05d8\u05d9\u05d5\u05dc \u05e9\u05dc \u05e2\u05d3\u05dc\u05d9\u05d4 \u05dc\u05d1\u05d5\u05e1\u05d8\u05d5\u05df \u05d1\u05e1\u05d5\u05e3 \u05d4\u05e9\u05d1\u05d5\u05e2 \u05d4\u05d6\u05d4, \u05e9\u05d0\u05e0\u05d9 \u05d0\u05e4\u05d9\u05dc\u05d5 \u05dc\u05d0 \u05d9\u05db\u05d5\u05dc \u05dc\u05d4\u05ea\u05d7\u05d9\u05dc \u05dc\u05d4\u05e7\u05dc\u05d9\u05d3 \u05d0\u05ea \u05d4\u05de\u05d9\u05dc\u05d9\u05dd \u05e9\u05dc \u05d0\u05d9\u05da \u05d0\u05e0\u05d7\u05e0\u05d5 \u05de\u05e8\u05d2\u05d9\u05e9\u05d9\u05dd<\/em>".<\/em><\/p>\n

<\/em><\/p>\n

\"\""\u05d4\u05ea\u05e8\u05d5\u05e4\u05d4 \u05d4\u05d7\u05d3\u05e9\u05d4 \u05d4\u05d6\u05d5 \u05dc\u05d6\u05da \u05e0\u05d5\u05ea\u05e0\u05ea \u05dc\u05e0\u05d5 \u05ea\u05e7\u05d5\u05d5\u05d4 \u05de\u05d7\u05d5\u05d3\u05e9\u05ea \u05e9\u05d4\u05dc\u05d1 \u05e9\u05dc\u05d5 \u05d9\u05d4\u05d9\u05d4 \u05d7\u05d6\u05e7 \u05d9\u05d5\u05ea\u05e8, \u05d4\u05d7\u05d9\u05d5\u05da \u05e9\u05dc\u05d5 \u05d9\u05d4\u05d9\u05d4 \u05d6\u05d5\u05d4\u05e8 \u05d9\u05d5\u05ea\u05e8 \u05d5\u05d7\u05d9\u05d9\u05d5 \u05d9\u05d4\u05d9\u05d5 \u05d0\u05e8\u05d5\u05db\u05d9\u05dd \u05d9\u05d5\u05ea\u05e8. \u05e0\u05d9\u05e1\u05d5\u05d9 \u05d4\u05ea\u05e8\u05d5\u05e4\u05d5\u05ea \u05d4\u05d7\u05d3\u05e9 \u05d4\u05d6\u05d4 \u05d4\u05d5\u05d0 \u05ea\u05e9\u05d5\u05d1\u05d4 \u05dc\u05ea\u05e4\u05d9\u05dc\u05d5\u05ea\u05d9\u05e0\u05d5. \u05ea\u05d5\u05d3\u05d4 \u05dc\u05db\u05dc \u05d4\u05de\u05e2\u05d5\u05e8\u05d1\u05d9\u05dd \u05d1-PRF \u05e9\u05d2\u05e8\u05de\u05d5 \u05dc\u05d6\u05d4 \u05dc\u05e7\u05e8\u05d5\u05ea... \u05d4\u05e8\u05d5\u05e4\u05d0\u05d9\u05dd, \u05d4\u05d7\u05d5\u05e7\u05e8\u05d9\u05dd \u05d5\u05d4\u05e6\u05d5\u05d5\u05ea. \u05d0\u05ea\u05dd \u05d4\u05d2\u05d9\u05d1\u05d5\u05e8\u05d9\u05dd \u05e9\u05dc\u05e0\u05d5!"<\/em><\/div>\n
\u00a0<\/div>\n
\n
\"\"

\u05e7\u05d0\u05dd \u05d5\u05d0\u05d1\u05d9\u05d5 \u05dc\u05d5\u05de\u05d3\u05d9\u05dd \u05db\u05d9\u05e6\u05d3 \u05dc\u05e2\u05e8\u05d1\u05d1 \u05d0\u05ea \u05d4\u05ea\u05e8\u05d5\u05e4\u05d4 FTI \u05e2\u05dd \u05de\u05de\u05ea\u05d9\u05e7.<\/p><\/div><\/p>\n

"\u05d1\u05e9\u05dd \u05e7\u05d0\u05dd \u05d5\u05d4\u05de\u05e9\u05e4\u05d7\u05d4 \u05e9\u05dc\u05e0\u05d5, \u05ea\u05d5\u05d3\u05d4 \u05e8\u05d1\u05d4 \u05dc\u05db\u05d5\u05dc\u05db\u05dd \u05d1-PRF \u05e2\u05dc \u05db\u05dc \u05de\u05d4 \u05e9\u05e2\u05e9\u05d9\u05ea\u05dd! \u05d4\u05d9\u05d9\u05e0\u05d5 \u05d4\u05d5\u05dc\u05db\u05d9\u05dd \u05dc\u05d0\u05d9\u05d1\u05d5\u05d3 \u05d1\u05e2\u05d5\u05dc\u05dd \u05e9\u05dc \u05d1\u05dc\u05d1\u05d5\u05dc \u05d5\u05d0\u05d1\u05dc \u05d1\u05dc\u05e2\u05d3\u05d9\u05da. \u05d1\u05de\u05e7\u05d5\u05dd \u05d6\u05d0\u05ea, \u05d0\u05e0\u05d5 \u05d7\u05d9\u05d9\u05dd \u05d1\u05e2\u05d5\u05dc\u05dd \u05e9\u05dc \u05ea\u05e7\u05d5\u05d5\u05d4 \u05d5\u05ea\u05db\u05dc\u05d9\u05ea. \u05ea\u05d5\u05d3\u05d4 \u05dc\u05da \u05e9\u05d5\u05d1 \u05d5\u05e9\u05d5\u05d1! \u05d1\u05d4\u05e8\u05d1\u05d4 \u05d0\u05d4\u05d1\u05d4 \u05d5\u05db\u05d1\u05d5\u05d3"<\/em><\/p>\n<\/div>\n

\u00a0<\/div>\n<\/div>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2009\/05\/HayleyMichielAmber-Aug09.jpg” title_text=”HayleyMichielAmber-Aug09″ _builder_version=”4.6.5″ _module_preset=”default” hover_enabled=”0″ align=”center” sticky_enabled=”0″ custom_margin=”||-4px|||”][\/et_pb_image][et_pb_text admin_label=”caption HM” _builder_version=”4.6.5″ _module_preset=”default” text_font_size=”12px”] Hayley from England and Michiel from Belgium are all smiles as they pose with their trophies for completing the first-ever Progeria clinical drug trial on Friday, August 14, 2009. They also, […]<\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"

[vc_custom_heading text=\"Moving Ahead at Lightening Speed as The Progeria Triple Drug Trial Begins!\" font_container=\"tag:h1|text_align:left\" use_theme_fonts=\"yes\"]<\/p>

[caption id=\"attachment_2083\" align=\"alignleft\" width=\"200\"]\"\" Hayley from England and Michiel from Belgium are all smiles as they pose with their trophies for completing the first-ever Progeria clinical drug trial on Friday, August 14, 2009. They also, along with Michiel\u2019s sister Amber (right), completed their first visit for the triple drug trial that week.[\/caption]

The Progeria Research Foundation and Children\u2019s Hospital Boston are once again partnering to conduct a second clinical trial for children with Progeria. This exciting and much larger trial includes 45 children from 24 countries, speaking 17 different languages!\u00a0<\/strong><\/p>

Summary<\/strong>: Researchers have identified two additional drugs that, when used in combination with the current FTI drug being tested, may provide an even more effective treatment for children with Progeria than FTI\u2019s alone.<\/p>

Scientific Basis for Treatment<\/strong><\/div>
Progeria is caused by an abnormal protein named progerin.\u00a0The Progeria research team at Children\u2019s Hospital Boston will add two drugs, called pravastatin and zoledronate, to the current treatment with FTI.<\/div>
\u00a0<\/div>
Strategy:<\/em><\/strong> All three drugs will target different points along the pathway leading to production of the disease-causing progerin.\u00a0In exciting laboratory studies presented by Dr. Carlos Lopez-Otin of Spain at the 2007 Progeria Research Foundation Scientific Workshop, the two new drugs improved disease in Progeria cells and extended lifespan in mouse models of Progeria.<\/div>
\u00a0<\/strong><\/div>
Goal:<\/em><\/strong> If the three drugs administered in this trial can effectively block this farnesyl group attachment, then progerin may be \u201cparalyzed\u201d and Progeria may be improved.\u00a0We hope that the drugs will work as partners, to complement each other so that the progerin protein is affected more by combining the three drugs than using any one drug alone.<\/div>
\u00a0<\/div>
Who is Enrolled in the Triple Drug Trial?<\/strong><\/div>
The Feasibility Trial:<\/strong>\u00a0The team has already conducted a mini-trial for 5 children with Progeria.\u00a0The short, one month \u201cfeasibility\u201d trial, asked whether the three-drug combination would be well-tolerated, prior to embarking on a larger international trial.\u00a0Side effects were acceptable, and the team has moved ahead to the larger efficacy trial.<\/div>
The Efficacy Trial:<\/strong> In Janaury 2010, the triple trial beamce fully enrolled with 45 children. This includes children participating in the FTI-only trial, the 5 in the feasibility trial, and other children that were either too young to participate in the first trial or children that we\u2019ve discovered over the past 2 years. Children enrolled in the FTI-only trial had the opportunity to enroll in the triple trial when they arrived for that first trial.\u00a0This allowed the children to continue taking FTI without any missed doses.<\/div>
\u00a0<\/strong><\/div>
The Treatment\/Progeria Relationship<\/strong><\/div>
How did we get from gene discovery to drug therapy for children with Progeria?\u00a0Finding the gene for Progeria was the key. This gene is called LMNA<\/em>, and it normally encodes a protein called prelamin A (this protein is further processed and becomes lamin A). Children with Progeria have a mutation in LMNA<\/em> which leads to the production of an abnormal form of prelamin A called \u201cprogerin.\u201d \u00a0Many years\u2019 worth of basic research on prelamin A and lamin A gave us the ability to understand that the drugs administered in this trial may affect disease in Progeria. \u00a0Over the past six years, research has focused on systematically testing these drugs on Progeria cells and Progeria mice.<\/div>
\u00a0<\/div>
The Clinical Trial Team<\/strong><\/div>
Since May 2007, a 28-member team has treated children with Progeria from around the globe.\u00a0Members of the team have expertise not only in Progeria, but also in the three drugs administered in this trial.<\/div>
\u00a0<\/strong><\/div>
Trial Medications at a Glance<\/strong><\/div>
Pravastatin<\/strong> (marketed as Pravachol or Selektine) is a member of the drug class of statins.\u00a0It is usually used for lowering cholesterol and preventing cardiovascular disease.<\/div>
Zoledronic acid <\/strong>is a bisphosphonate, <\/strong>usually used as a bone drug for improving osteoporosis, and to prevent skeletal fractures in people suffering from some forms of cancer.<\/div>
Lonafarnib<\/strong> is an FTI<\/strong> (Farnesyltransferase inhibitor), a drug that can reverse an abnormality in Progeria cells in the laboratory, and has improved disease in Progeria mice.<\/div>
All 3 drugs block the production of the farnesyl molecule that is needed for progerin to create disease in Progeria.<\/em><\/div>
\u00a0<\/strong><\/div>
Timing<\/strong><\/div>
Patients are traveling to Boston for testing and examinations lasting 4-7 days, every 6 months for a period of 2 years. For the FTI-only trial, Boston visits occurred every four months.<\/div>
\u00a0<\/strong><\/div>
Cost<\/strong>
Of course, a clinical trial of this magnitude is expensive to manage, and there are precious few sources of support for rare disease research.\u00a0 But in October 2009, the NIH's National Heart, Lung, and Blood Institute awarded the triple trial team a prestigious \"Grand Opportunities\" grant that will cover many of the costs.\u00a0 We are thrilled to have earned this extraordinary support from NIH.<\/div>

However, the grant doesn't cover all of the trial expenses.\u00a0 PRF still needs to raise about $150,000 for some costs not covered by the grant.<\/p>

Click here<\/a> to donate to the triple drug trial and help make the GOAL of treatment and cure a REALITY!
<\/strong><\/p><\/div>

* <\/em>\u201cCombined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging\u201d,<\/strong> by Ignacio Varela, Sandrine Pereira, Alejandro P. Ugalde, Claire L. Navarro, Mar\u00c4\u00b1a F. Suarez, Pierre Cau, Juan Cadinanos, Fernando G. Osorio, Nicolas Foray, Juan Cobo, Felix de Carlos, Nicolas Levy, Jose MP Freije and Carlos Lopez-Ot\u00c4\u00b1n. Nature Medicine, <\/em>2008. 14(7): p. 767-72.<\/em><\/div>
\u00a0<\/em>
<\/em>T<\/strong>he new generation of children PRF is helping\u2026<\/strong><\/div>
In March, 2009, five children, ages 2-3, participated in a one-month feasibility study to determine if the side effects of the three drugs taken together were tolerable.\u00a0The results were positive, paving the way for the full, two-year, Triple Drug Trial to enroll up to 45 children with Progeria.\u00a0Hats off to these amazing families!<\/strong><\/div>
\u00a0<\/strong><\/div>
Here is what some of them had to say:<\/strong><\/div>

\"\"\u201c<\/em>EVERYONE has been so wonderful.\u00a0 To us you are ALL GOD SENT and we APPRECIATE all that you do for these little angels.\u00a0 Our family is so overwhelmed with excitement and all sorts of emotions with Adalia\u2019s trip to Boston this weekend, I can\u2019t even begin to type the words of how we are feeling<\/em>\u201d.<\/em><\/p><\/div>

\"\"\u201cThis new medication for Zach gives us a renewed hope that his heart will be stronger, his smile will be brighter and his life will be longer.\u00a0 This new drug trial is an answer to our prayers. \u00a0 Thank you to everyone involved with PRF who made this happen...the doctors, the researchers and the staff.\u00a0 You are our heroes!\u201d<\/em><\/div>
\u00a0<\/div>
\u00a0<\/div>
\u00a0<\/div>
\u00a0<\/div>
[caption id=\"attachment_2086\" align=\"alignright\" width=\"150\"]\"\" Cam and his dad learn how to mix the FTI drug with a sweetener.[\/caption]

\u201cOn behalf of Cam and our family, thank you all at PRF so much for all you have done!\u00a0 We would have been lost in a world of confusion and grief without you.\u00a0 Instead, we live in a world of hope and purpose.\u00a0 Thank you again and again!\u00a0\u00a0With much love and respect,\u201d<\/em><\/p><\/div>

\u00a0<\/div><\/div>","_et_gb_content_width":"","footnotes":"","_links_to":"","_links_to_target":""},"categories":[2],"tags":[],"class_list":["post-2082","post","type-post","status-publish","format-standard","hentry","category-news"],"yoast_head":"\nMoving Ahead at Lightening Speed as The Progeria Triple Drug Trial Begins! - The Progeria Research Foundation<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.progeriaresearch.org\/he\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/\" \/>\n<meta property=\"og:locale\" content=\"he_IL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Moving Ahead at Lightening Speed as The Progeria Triple Drug Trial Begins! - The Progeria Research Foundation\" \/>\n<meta property=\"og:description\" content=\"[et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2009\/05\/HayleyMichielAmber-Aug09.jpg” title_text=”HayleyMichielAmber-Aug09″ _builder_version=”4.6.5″ _module_preset=”default” hover_enabled=”0″ align=”center” sticky_enabled=”0″ custom_margin=”||-4px|||”][\/et_pb_image][et_pb_text admin_label=”caption HM” _builder_version=”4.6.5″ _module_preset=”default” text_font_size=”12px”] Hayley from England and Michiel from Belgium are all smiles as they pose with their trophies for completing the first-ever Progeria clinical drug trial on Friday, August 14, 2009. They also, […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.progeriaresearch.org\/he\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/\" \/>\n<meta property=\"og:site_name\" content=\"The Progeria Research Foundation\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ProgeriaResearch\/\" \/>\n<meta property=\"article:published_time\" content=\"2009-05-16T13:36:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2020-12-10T21:44:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2017\/05\/AdaliaJAN09.jpg\" \/>\n<meta name=\"author\" content=\"gravoc\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@Progeria\" \/>\n<meta name=\"twitter:site\" content=\"@Progeria\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"gravoc\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 \u05d3\u05e7\u05d5\u05ea\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/\"},\"author\":{\"name\":\"gravoc\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/a3c935a81e92242c6a77ae0018542928\"},\"headline\":\"Moving Ahead at Lightening Speed as The Progeria Triple Drug Trial Begins!\",\"datePublished\":\"2009-05-16T13:36:57+00:00\",\"dateModified\":\"2020-12-10T21:44:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/\"},\"wordCount\":1251,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2017\/05\/AdaliaJAN09.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"he-IL\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/\",\"name\":\"Moving Ahead at Lightening Speed as The Progeria Triple Drug Trial Begins! - The Progeria Research Foundation\",\"isPartOf\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2017\/05\/AdaliaJAN09.jpg\",\"datePublished\":\"2009-05-16T13:36:57+00:00\",\"dateModified\":\"2020-12-10T21:44:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#breadcrumb\"},\"inLanguage\":\"he-IL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"he-IL\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#primaryimage\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2017\/05\/AdaliaJAN09.jpg\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2017\/05\/AdaliaJAN09.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.progeriaresearch.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Moving Ahead at Lightening Speed as The Progeria Triple Drug Trial Begins!\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#website\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"name\":\"The Progeria Research Foundation\",\"description\":\"For the Children \u2665 For the Cure\",\"publisher\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"he-IL\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#organization\",\"name\":\"The Progeria Research Foundation\",\"url\":\"https:\/\/www.progeriaresearch.org\/ta\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"he-IL\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"contentUrl\":\"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png\",\"width\":300,\"height\":86,\"caption\":\"The Progeria Research Foundation\"},\"image\":{\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/ProgeriaResearch\/\",\"https:\/\/x.com\/Progeria\",\"https:\/\/www.instagram.com\/progeriaresearch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/a3c935a81e92242c6a77ae0018542928\",\"name\":\"gravoc\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"he-IL\",\"@id\":\"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/cee2d206466fdbfc70635d168190f07f615d6e9c97c316eb6a88b5b563efdd7b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/cee2d206466fdbfc70635d168190f07f615d6e9c97c316eb6a88b5b563efdd7b?s=96&d=mm&r=g\",\"caption\":\"gravoc\"},\"url\":\"https:\/\/www.progeriaresearch.org\/he\/author\/gravoc\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Moving Ahead at Lightening Speed as The Progeria Triple Drug Trial Begins! - The Progeria Research Foundation","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.progeriaresearch.org\/he\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/","og_locale":"he_IL","og_type":"article","og_title":"Moving Ahead at Lightening Speed as The Progeria Triple Drug Trial Begins! - The Progeria Research Foundation","og_description":"[et_pb_section fb_built=”1″ _builder_version=”3.22″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_image src=”https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2009\/05\/HayleyMichielAmber-Aug09.jpg” title_text=”HayleyMichielAmber-Aug09″ _builder_version=”4.6.5″ _module_preset=”default” hover_enabled=”0″ align=”center” sticky_enabled=”0″ custom_margin=”||-4px|||”][\/et_pb_image][et_pb_text admin_label=”caption HM” _builder_version=”4.6.5″ _module_preset=”default” text_font_size=”12px”] Hayley from England and Michiel from Belgium are all smiles as they pose with their trophies for completing the first-ever Progeria clinical drug trial on Friday, August 14, 2009. They also, […]","og_url":"https:\/\/www.progeriaresearch.org\/he\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/","og_site_name":"The Progeria Research Foundation","article_publisher":"https:\/\/www.facebook.com\/ProgeriaResearch\/","article_published_time":"2009-05-16T13:36:57+00:00","article_modified_time":"2020-12-10T21:44:57+00:00","og_image":[{"url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2017\/05\/AdaliaJAN09.jpg","type":"","width":"","height":""}],"author":"gravoc","twitter_card":"summary_large_image","twitter_creator":"@Progeria","twitter_site":"@Progeria","twitter_misc":{"Written by":"gravoc","Est. reading time":"6 \u05d3\u05e7\u05d5\u05ea"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#article","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/"},"author":{"name":"gravoc","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/a3c935a81e92242c6a77ae0018542928"},"headline":"Moving Ahead at Lightening Speed as The Progeria Triple Drug Trial Begins!","datePublished":"2009-05-16T13:36:57+00:00","dateModified":"2020-12-10T21:44:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/"},"wordCount":1251,"commentCount":0,"publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2017\/05\/AdaliaJAN09.jpg","articleSection":["News"],"inLanguage":"he-IL","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/","url":"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/","name":"Moving Ahead at Lightening Speed as The Progeria Triple Drug Trial Begins! - The Progeria Research Foundation","isPartOf":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#primaryimage"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#primaryimage"},"thumbnailUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2017\/05\/AdaliaJAN09.jpg","datePublished":"2009-05-16T13:36:57+00:00","dateModified":"2020-12-10T21:44:57+00:00","breadcrumb":{"@id":"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#breadcrumb"},"inLanguage":"he-IL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/"]}]},{"@type":"ImageObject","inLanguage":"he-IL","@id":"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#primaryimage","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2017\/05\/AdaliaJAN09.jpg","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2017\/05\/AdaliaJAN09.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.progeriaresearch.org\/2009\/05\/16\/moving-ahead-at-lightening-speed-as-the-progeria-triple-drug-trial-begins\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.progeriaresearch.org\/"},{"@type":"ListItem","position":2,"name":"Moving Ahead at Lightening Speed as The Progeria Triple Drug Trial Begins!"}]},{"@type":"WebSite","@id":"https:\/\/www.progeriaresearch.org\/ta\/#website","url":"https:\/\/www.progeriaresearch.org\/ta\/","name":"\u05e7\u05e8\u05df \u05d4\u05de\u05d7\u05e7\u05e8 \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4","description":"\u05dc\u05d9\u05dc\u05d3\u05d9\u05dd \u2665 \u05dc\u05e8\u05d9\u05e4\u05d5\u05d9","publisher":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.progeriaresearch.org\/ta\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"he-IL"},{"@type":"Organization","@id":"https:\/\/www.progeriaresearch.org\/ta\/#organization","name":"\u05e7\u05e8\u05df \u05d4\u05de\u05d7\u05e7\u05e8 \u05e4\u05e8\u05d5\u05d2\u05e8\u05d9\u05d4","url":"https:\/\/www.progeriaresearch.org\/ta\/","logo":{"@type":"ImageObject","inLanguage":"he-IL","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/","url":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","contentUrl":"https:\/\/www.progeriaresearch.org\/wp-content\/uploads\/2019\/05\/PRF_Logo_2019_optimized.png","width":300,"height":86,"caption":"The Progeria Research Foundation"},"image":{"@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ProgeriaResearch\/","https:\/\/x.com\/Progeria","https:\/\/www.instagram.com\/progeriaresearch\/"]},{"@type":"Person","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/a3c935a81e92242c6a77ae0018542928","name":"\u05d2\u05e8\u05d1\u05d5\u05e7","image":{"@type":"ImageObject","inLanguage":"he-IL","@id":"https:\/\/www.progeriaresearch.org\/ta\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/cee2d206466fdbfc70635d168190f07f615d6e9c97c316eb6a88b5b563efdd7b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/cee2d206466fdbfc70635d168190f07f615d6e9c97c316eb6a88b5b563efdd7b?s=96&d=mm&r=g","caption":"gravoc"},"url":"https:\/\/www.progeriaresearch.org\/he\/author\/gravoc\/"}]}},"_links":{"self":[{"href":"https:\/\/www.progeriaresearch.org\/he\/wp-json\/wp\/v2\/posts\/2082","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.progeriaresearch.org\/he\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.progeriaresearch.org\/he\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/he\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/he\/wp-json\/wp\/v2\/comments?post=2082"}],"version-history":[{"count":0,"href":"https:\/\/www.progeriaresearch.org\/he\/wp-json\/wp\/v2\/posts\/2082\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.progeriaresearch.org\/he\/wp-json\/wp\/v2\/media?parent=2082"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/he\/wp-json\/wp\/v2\/categories?post=2082"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.progeriaresearch.org\/he\/wp-json\/wp\/v2\/tags?post=2082"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}